Rapid generation of dityrosine cross-linked aβ oligomers via cu-redox cycling

Methods in Molecular Biology

Volumn 849, Issue , 2012, Pages 3-10

  Gunn, Adam P ^a   Roberts, Blaine R ^a   Bush, Ashley I ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

A ; Alzheimer's disease; Amyloid beta; Copper; Dityrosine; Hydroxyl radical

Indexed keywords

AMYLOID BETA PROTEIN; ASCORBIC ACID; COPPER; DITYROSINE; TYROSINE DERIVATIVE; UNCLASSIFIED DRUG; AMYLOID BETA PROTEIN (1 42); AMYLOID BETA-PROTEIN (1-42); CROSS LINKING REAGENT; DRUG DERIVATIVE; HYDROXYL RADICAL; PEPTIDE FRAGMENT; TYROSINE;

ALZHEIMER DISEASE; ARTICLE; CROSS LINKING; IMMUNODETECTION; OXIDATION REDUCTION REACTION; PRIORITY JOURNAL; REPRODUCIBILITY; CHEMISTRY; DRUG EFFECT; IMMUNOBLOTTING; KINETICS; METABOLISM; PROTEIN MULTIMERIZATION; PROTEIN SECONDARY STRUCTURE; SPECTROFLUOROMETRY;

AMYLOID BETA-PEPTIDES; ASCORBIC ACID; COPPER; CROSS-LINKING REAGENTS; HYDROXYL RADICAL; IMMUNOBLOTTING; KINETICS; OXIDATION-REDUCTION; PEPTIDE FRAGMENTS; PROTEIN MULTIMERIZATION; PROTEIN STRUCTURE, SECONDARY; SPECTROMETRY, FLUORESCENCE; TYROSINE;

EID: 84864610100     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-61779-551-0_1     Document Type: Article

References (21)

1. Dong J, Atwood CS, Anderson VE, Siedlak SL, Smith MA, Perry G and P.R. Carey (2003) Metal binding and oxidation of amyloid-beta within isolated senile plaque cores: Raman microscopic evidence, Biochemistry 42 , 2768-2773
2. Lue L-F, Kuo Y-M, Roher AE, et al. (1999) Soluble amyloid b peptide concentration as a predictor of synaptic change in Alzheimer's disease. Am J Pathol 155 , 853-862
3. Wang J, Dickson DW, Trojanowski JQ, Lee VM (1999) The levels of soluble versus insoluble brain A b distinguish Alzheimer's disease from normal and pathologic aging. Experimental Neurology 158 , 328-337
4. McLean CA, Cherny RA, Fraser FW, Fuller SJ, Smith MJ, et al. (1999) Soluble pool of A b amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann Neurol 46 , 860-866
5. Portelius E, Bogdanovic N, Gustavsson MK, Volkmann I, Brinkmalm G, et al. (2010) Mass spectrometric characterization of brain amyloid beta isoform signatures in familial and sporadic Alzheimer's disease. Acta Neuropathol
6. Guntert A, Dobeli H, Bohrmann B (2006) High sensitivity analysis of amyloid-beta peptide composition in amyloid deposits from human and PS2APP mouse brain. Neuroscience 143 , 461-475
7. Roher AE, Lowenson JD, Clarke S, Wolkow C, Wang R, et al. (1993) Structural alterations in the peptide backbone of b-amyloid core protein may account for its deposition and stability in Alzheimer's disease. J Biol Chem 268, 3072-3083
8. Kaneko I, Morimoto K, Kubo T (2001) Drastic neuronal loss in vivo by b-amyloid racemized at Ser(26) residue: conversion of non-toxic (D-Ser(26)) b-amyloid 1-40 to toxic and proteinase-resistant fragments. Neuroscience 104 , 1003-1011
9. Saido TC, Iwatsubo T, Mann DM, Shimada H, Ihara Y, et al. (1995) Dominant and differential deposition of distinct b-amyloid peptide species, A b N3(pE) , in senile plaques. Neuron 14, 457-466
10. Piccini A, Russo C, Gliozzi A, Relini A, Vitali A, et al. (2005) Beta amyloid is different in normal aging and in Alzheimer disease. J Biol Chem 280, 34186-34192
11. Head E, Garzon-Rodriguez W, Johnson JK, Lott IT, Cotman CW, et al. (2001) Oxidation of A b and plaque biogenesis in Alzheimer's disease and Down syndrome. Neurobiol Dis 8 , 792-806
12. Butterfi eld DA, Perluigi M, Sultana R (2006) Oxidative stress in Alzheimer's disease brain: new insights from redox proteomics. Eur J Pharmacol 545, 39-50
13. Bush AI, Tanzi RE (2008) Therapeutics for Alzheimer's disease based on the metal hypothesis. Neurotherapeutics 5 , 421-432
14. Nunomura A, Perry G, Aliev G, Hirai K, Takeda A, et al. (2001) Oxidative damage is the earliest event in Alzheimer disease. J. Neuropath. Exp. Neurology 60 , 759-767
15. Pratico D, Uryu K, Leight S, Trojanoswki JQ, Lee VM (2001) Increased lipid peroxidation precedes amyloid plaque formation in an animal model of Alzheimer amyloidosis. J Neurosci 21 , 4183-4187
16. Duce JA, Bush AI (2010) Biological metals and Alzheimer's disease: implications for therapeutics and diagnostics. Prog Neurobiol 92, 1-18
17. Atwood CS, Moir RD, Huang X, Scarpa RC, Bacarra NM, et al. (1998) Dramatic aggregation of Alzheimer A b by Cu(II) is induced by conditions representing physiological acidosis. J Biol Chem 273 , 12817-12826
18. Schapira AH (1996) Oxidative stress and mitochondrial dysfunction in neurodegeneration. Curr Opin Neurol 9 , 260-264
19. Sparks DL (1997) Coronary artery disease, hypertension, ApoE, and cholesterol: A link to Alzheimer's disease? Ann N Y Acad Sci 826 , 128-146
20. Atwood CS, Scarpa RC, Huang X, Moir RD, Jones WD, et al. (2000) Characterization of copper interactions with Alzheimer amyloid b peptides: identifi cation of an attomolar-affi nity copper binding site on amyloid beta1-42. J Neurochem 75, 1219-1233
21. Barnham KJ, Haeffner F, Ciccotosto GD, Curtain CC, Tew D, et al. (2004) Tyrosine gated electron transfer is key to the toxic mechanism of Alzheimer's disease b-amyloid. FASEB J 18 , 1427-1429